Abstract
The use of antiplatelet medications, such as acetylsalicylic acid (ASA), a combination of dipyridamol with ASA and also clopidogrel, is of great importance for the secondary prevention of ischemic stroke or transient ischemic attacks. In addition to the known form of clopidogrel hydrogen sulfate (CHS) a further clopidogrel salt, clopidogrel besylate (CB), has also been available since May 2008. The presented case illustrates that in patients with a history of cerebrovascular disease the antiplatelet response of CB can be diminished in comparison to CHS. Therefore we recommend testing the antiplatelet effectiveness when changing patient medication from CHS to CB.
Publication types
-
Case Reports
-
Comparative Study
MeSH terms
-
Aged
-
Cerebral Infarction / diagnosis
-
Cerebral Infarction / prevention & control*
-
Clopidogrel
-
Drug Resistance
-
Humans
-
Ischemic Attack, Transient / diagnosis
-
Ischemic Attack, Transient / prevention & control*
-
Male
-
Neurologic Examination / drug effects
-
Platelet Aggregation / drug effects
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Structure-Activity Relationship
-
Therapeutic Equivalency
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / chemistry
-
Ticlopidine / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine